Ling Chen

Address:

2250 Patterson St UNIT 199, Eugene, OR 97405

Phone:

5419532688

VIN:

4JGBF2FE7CA785455

Make:

MERCEDES-BENZ

Model:

GL-CLASS

Year:

2012

US Patent:

6733993, May 11, 2004

Filed:

Sep 14, 2001

Appl. No.:

09/952060

Inventors:

Emilio A. Emini - Wayne PA
Rima Youil - North Wales PA
Andrew J. Bett - Landsdale PA
Ling Chen - Blue Bell PA
David C. Kaslow - Bryn Mawr PA
John W. Shiver - Doylestown PA
Timothy J. Toner - Marlton NJ
Danilo R. Casimiro - Harleysville PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C12P 2106

US Classification:

435 691, 435 5, 435 71, 435325, 4353391, 53038835, 536 231, 4241991, 4242081

Abstract:

First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

US Patent:

6787351, Sep 7, 2004

Filed:

Mar 27, 2001

Appl. No.:

09/818443

Inventors:

Ling Chen - Blue Bell PA
John W. Shiver - Doylestown PA
Andrew J. Bett - Lansdale PA
Danilo R. Casimiro - Harleysville PA
Michael J. Caulfield - Fort Washington PA
Michael A. Chastain - Glenside PA
Emilio A. Emini - Strafford PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C12N 1574

US Classification:

4353201, 435 691, 435 692, 424 932

Abstract:

An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.

US Patent:

6916812, Jul 12, 2005

Filed:

Oct 4, 2002

Appl. No.:

10/264709

Inventors:

Graham S. Poindexter - Old Saybrook CT, US
Guanglin Luo - Madison CT, US
Ling Chen - Middletown CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K031/495
A61K031/496
C07D295/192
C07D405/10
C07D409/10

US Classification:

5142358, 51425301, 51425409, 5142541, 51425501, 51425306, 51425405, 51425408, 51425411, 514218, 544121, 544360, 544363, 544364, 544370, 544373, 544372, 544376, 544377, 544379, 544380, 544391, 540575

Abstract:

Novel piperazine and homopiperazine derivatives are agonists of melanocortin receptor(s) and are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of the melanocortin receptors. The compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders such as obesity, diabetes, and sexual dysfunction.

US Patent:

7001995, Feb 21, 2006

Filed:

Aug 21, 2000

Appl. No.:

09/642405

Inventors:

Michael P Neeper - Collegeville PA, US
William L. McClements - Doylestown PA, US
Kathrin U. Jansen - Doylestown PA, US
Loren D. Schultz - Harleysville PA, US
Ling Chen - Blue Bell PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07H 21/04
C12N 15/74
A61K 48/00
C12P 21/06

US Classification:

536 231, 4353201, 435 691, 424 9321, 514 44

Abstract:

Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.

US Patent:

7211569, May 1, 2007

Filed:

Dec 4, 2003

Appl. No.:

10/728131

Inventors:

Michael P Neeper - Collegeville PA, US
William L. McClements - Doylestown PA, US
Kathrin U. Jansen - Doylestown PA, US
Loren D. Schultz - Harleysville PA, US
Ling Chen - Blue Bell PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 48/00
C07H 21/04

US Classification:

514 44, 435 691, 4353201, 536 231, 424 9321

Abstract:

Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.

US Patent:

7220862, May 22, 2007

Filed:

Dec 5, 2003

Appl. No.:

10/729155

Inventors:

Prasad V. Chaturvedula - Cheshire CT, US
Ling Chen - Middletown CT, US
Rita Civiello - Killingworth CT, US
Andrew P. Degnan - New Haven CT, US
Gene M. Dubowchik - Middlefield CT, US
Xiaojun Han - Cheshire CT, US
Xiang Jun J. Jiang - Hamden CT, US
George N. Karageorge - Portland CT, US
Guanglin Luo - Madison CT, US
John E. Macor - Guilford CT, US
Graham Poindexter - Old Saybrook CT, US
George Tora - Meriden CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/14
C07D 487/22
A61K 31/4427
A61K 31/496
A61K 31/517
A61P 11/00
A61P 11/06
A61P 25/06

US Classification:

546196, 546197, 546198, 546200, 546201, 544 92, 544283, 5142305, 5142308, 5142662, 514320

Abstract:

The present invention relates to compounds of Formula (I).

US Patent:

7314883, Jan 1, 2008

Filed:

Jan 5, 2007

Appl. No.:

11/620291

Inventors:

Ling Chen - Middletown CT, US
Prasad V. Chaturvedula - Cheshire CT, US
Rita Civiello - Killingworth CT, US
Andrew P. Degnan - Rocky Hill CT, US
Gene M. Dubowchik - Middlefield CT, US
Xiaojun Han - Cheshire CT, US
Xiang Jun J. Jiang - North Haven CT, US
George N. Karageorge - Portland CT, US
Guanglin Luo - Madison CT, US
John E. Macor - Guilford CT, US
Graham S. Poindexter - Old Saybrook CT, US
George O. Tora - Meriden CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/4427
A61K 31/496
A61K 31/517
A61P 11/00
A61P 11/06
A61P 25/06
C07D 487/14
C07D 487/22

US Classification:

514320, 5142662, 5142305, 5142308, 544 92, 544283, 546198, 546200, 546201

Abstract:

The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammaton, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I).

US Patent:

7569578, Aug 4, 2009

Filed:

Dec 3, 2004

Appl. No.:

11/004706

Inventors:

Guanglin Luo - Madison CT, US
Ling Chen - Middletown CT, US
Andrew P. Degnan - New Haven CT, US
Gene M. Dubowchik - Middlefield CT, US
John E. Macor - Guilford CT, US
George O. Tora - Meriden CT, US
Prasad V. Chaturvedula - Cheshire CT, US

Assignee:

Bristol-Meyers Squibb Company - Princeton NJ

International Classification:

A61K 31/517
C07D 239/95
A61K 31/497
C07D 403/04

US Classification:

51426622, 5142663, 544286

Abstract:

The present invention relates to compounds of Formula (I).